Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7616222 | 0.98 | CXCR4 (0.38) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL1782169 | 0.93 | — | — | |
| SCHEMBL2260970 | 0.93 | — | — | |
| SCHEMBL16100819 | 0.85 | — | — | |
| SCHEMBL16100820 | 0.85 | — | — | |
| SCHEMBL16583914 | 0.83 | — | — | |
| SCHEMBL1780706 | 0.82 | HIF1A (0.33) | — | |
| SCHEMBL1781456 | 0.82 | HIF1A (0.33) | — | |
| SCHEMBL625882 | 0.82 | HIF1A (0.33) | — | |
| SCHEMBL12095338 | 0.82 | HIF1A (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118234720-A | Radiolabeled fibroblast activation protein ligand | 菲罗化学股份公司 | 2024-06-21 | — | — | CN | claimed |
| CN-114832119-B | Radioactive gel microsphere and preparation method and application thereof | 苏州大学 | 2024-02-09 | — | — | CN | claimed |
| CN-117460528-A | anti-CLDN 18.2 antibody conjugates | 苏州创胜医药集团有限公司 | 2024-01-26 | — | — | CN | claimed |
| EP-4294441-A1 | ANTI-CLDN18.2 ANTIBODY CONJUGATES | Suzhou Transcenta Therapeutics Co., Ltd. (CN) | 2023-12-27 | — | — | EP | claimed |
| CN-116917278-A | Divalent fibroblast activation protein ligands for targeted delivery applications | 菲罗化学股份公司 | 2023-10-20 | — | — | CN | claimed |
| CN-115721742-A | Radioactive immunoconjugates and their use for bone marrow pretreatment or treatment of bone marrow related diseases | 塞拉法尔目有限责任公司 | 2023-03-03 | — | — | CN | claimed |
| CN-115335370-A | Fibroblast activation protein ligands for targeted delivery applications | 菲洛谢姆股份公司 | 2022-11-11 | — | — | CN | claimed |
| WO-2022174809-A1 | ANTI-CLDN18.2 ANTIBODY CONJUGATES | Suzhou Transcenta Therapeutics Co., Ltd. (CN) | 2022-08-25 | — | — | WO | claimed |
| CN-114832119-A | Radioactive gel microsphere and preparation method and application thereof | 苏州大学 | 2022-08-02 | — | — | CN | claimed |
| US-11000604-B2 | Reagent for site-selective bioconjugation of proteins or antibodies | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2021-05-11 | — | — | US | claimed |
| CN-112601740-A | Radioactive compounds for the treatment of melanoma and uses thereof | 全南大学校产学协力团 | 2021-04-02 | — | — | CN | claimed |
| US-20200397928-A1 | REAGENT FOR SITE-SELECTIVE BIOCONJUGATION OF PROTEINS OR ANTIBODIES | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK | 2020-12-24 | — | — | US | claimed |
| CN-111808161-A | Method for radiolabeling biological compounds | 北京大学 | 2020-10-23 | — | — | CN | claimed |
| US-7205385-B2 | magnetic resonance imaging agents; poly(amino acid-imaging agent) product can be obtained in high purity without a rigorous purification since all impurities are removed at the monomer synthesis stage | GENERAL ELECTRIC COMPANY (US) | 2007-04-17 | — | — | US | claimed |
| EP-0584256-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR DETECTING AND LOCALIZING TISSUES HAVING NEUROKININE 1 RECEPTORS | MALLINCKRODT MEDICAL INC (US) | 1999-11-10 | — | — | EP | claimed |
| WO-1995026206-A1 | METHOD FOR PREPARING RADIONUCLIDE-LABELED CHELATING AGENT-LIGAND COMPLEXES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-10-05 | — | — | WO | claimed |
| US-5273743-A | A compound made up of three different Fab'-like fragments linked by a bis- or trissuccinimidyl moiety; retention of antigen binding acitivity | HYBRITECH INCORPORATED (US) | 1993-12-28 | — | — | US | claimed |
| US-20260021213-A1 | METHOD FOR PRODUCING FC-CONTAINING MOLECULE MODIFYING REAGENT | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2026-01-22 | — | — | US | disclosed |
| EP-0433312-A1 | CARRIER SYSTEM AND METHOD FOR ENHANCEMENT OF MAGNETIC RESONANCE IMAGING | THE UNIVERSITY OF CONNECTICUT (US) | 1991-06-26 | — | — | EP | disclosed |
| WO-1990001900-A1 | CARRIER SYSTEM AND METHOD FOR ENHANCEMENT OF MAGNETIC RESONANCE IMAGING | THE UNIVERSITY OF CONNECTICUT (US) | 1990-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397928-A1 | REAGENT FOR SITE-SELECTIVE BIOCONJUGATION OF PROTEINS OR ANTIBODIES | MRPL21, TFRC, ARGLU1 | CXCR4 2100/4885SMN1; SMN2 2820/4885ALDH1A1 835/4885 |
| US-11000604-B2 | Reagent for site-selective bioconjugation of proteins or antibodies | MRPL21, TFRC, ARGLU1 | CXCR4 2100/4885SMN1; SMN2 2820/4885ALDH1A1 835/4885 |
| US-20260021213-A1 | METHOD FOR PRODUCING FC-CONTAINING MOLECULE MODIFYING REAGENT | PTMS, FCGR1A, F13B | CXCR4 1349/4885SMN1; SMN2 4013/4885ALDH1A1 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.